Onco Actu du 26 février 2019

	2.6 ETIOLOGIE - ENVIRONNEMENT
Brazil health officials find weed-killer glyphosate non-cancerous [Reuters] Analysts at Brazil health agency Anvisa have determined that the weed-killer glyphosate does not cause cancer while recommending a series of precautions be adopted in its use, amid growing international pressure to reduce use of the chemical.
	3.1 PRÉVENTION - TABAC
How big tobacco keeps cancer rates high in countries like mine [The Guardian] The industry has lost the battle against regulation in the west, so is desperate to prevent Bangladesh from imposing vital taxes.
	4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...
FDA issues warning letter to clinic illegally marketing unapproved thermography device, warns consumers to avoid using thermography devices to detect breast cancer [FDA] Total Thermal Imaging Inc. illegally marketed the unapproved device via a website and promotional materials claiming that its device can enable the early detection or the diagnosis of many disorders including breast cancer, inflammatory breast cancer, pre-stroke, heart disease, deep vein thrombosis and other diseases.
	4.12 BIOPSIES LIQUIDES
Breakthrough 'lab-on-a-chip' detects cancer faster, cheaper and less invasively [University of Kansas] The “lab-on-a-chip” for “liquid biopsy” analysis, reported today in Nature Biomedical Engineering, detects exosomes — tiny parcels of biological information produced by tumor cells to stimulate tumor growth or metastasize.
A New Sequencing Method To Detect DNA Modifications Of Relevance To Cancer [Ludwig Cancer Research] Song, Schuster-Boeckler and colleagues are now refining TAPS to analyze cell-free DNA shed by tumors into the bloodstream with the goal of applying the technique to develop minimally invasive cancer diagnostics.
	5. TRAITEMENTS
Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults [NCI] “The pediatric regimen will become the new standard treatment for young adults who are newly diagnosed with ALL,” Dr. Seibel said. “And, as we try to improve the treatment for ALL, this regimen will be the treatment against which other therapies are compared.”
Sperm Quality Unaffected by one Course of Chemotherapy for Early Testicular Cancer [Annals of Oncology Press Release] First study to investigate long-term effect of postoperative chemotherapy or radiotherapy on sperm count and concentration.
	5.10 TRAITEMENTS - ESSAIS
Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer [AstraZeneca] AstraZeneca and MSD plan to present the full data from the trial at a forthcoming medical meeting.
AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer [End Points] Months after securing a lightning fast approval for the use of the drug in frontline ovarian cancer — widening their lead over the cluster of other PARPs including Tesaro’s (now GSK’s) Zejula and Clovis’ Rubraca — Lynparza has shown promise in helping patients with BRCA-mutated metastatic pancreatic cancer live longer without their cancer progressing in a late-stage study.
AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study [Reuters] Lynparza was abandoned at one time by AstraZeneca, but was revived by Chief Executive Officer Pascal Soriot when he took over in 2012. The drug became the first PARP drug to reach the market when it won U.S. approval for ovarian cancer at the end of 2014.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Autolus taps Vineti to help deliver personalized cell therapies [Fierce Biotech] Three-year-old Vineti, co-founded by GE Ventures and Mayo Clinic Ventures, has developed cloud-based software to automate and orchestrate the many steps involved in the production and delivery of cell and gene therapies.
Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry [Cellectis] Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents monocyte-dependent release of key cytokine release syndrome mediators.
Temasek leads $85M round for Chinese biotech aiming for cheaper, faster, better CAR-T therapies [EndPoints] Gracell is itching to alleviate some of these constraints: high production costs, lengthy manufacturing process, a paucity of off-the-shelf products and a short duration of therapeutic effects, with its raft of early-stage CAR-T products. The notion is commendable, but there is a long road ahead.
	5.2 PHARMA
Genmab Announces Positive Topline Results in Phase III COLUMBA Study of Subcutaneous Daratumumab [Genmab] Results show that daratumumab administered subcutaneously was non-inferior in efficacy and pharmacokinetics as compared to daratumumab administered intravenously.
	5.3 TRAITEMENTS - FDA, EMA, NICE...
Can Roche’s little tech startup help the FDA change clinical trials? [STAT] Zach Weinberg, 32, Flatiron’s co-founder, president, and chief operating officer, believes in his tech in a big way. During an interview, he promised Flatiron will soon publish results showing it is possible to achieve one of the major goals of the field: using data collected from health records to mimic a control group.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Taiho] The approval for LONSURF follows an FDA Priority Review designation and is based on data from a global, randomized, Phase III TAGS trial evaluating LONSURF plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated advanced gastric cancer or GEJ adenocarcinoma following progression or intolerance to previous lines of standard therapy.
	5.4 TRAITEMENTS - ECONOMIE
Additional exclusivity for a cancer treatment could cost the public $3 billion, analyst says [EndPoints] Last week, the FDA granted additional exclusivity to Eagle Pharmaceuticals’ cancer medicine Treanda (bendamustine hydrochloride), a decision that effectively halts the introduction of generic versions of the injection until 2022, which one analyst said could cost the public $3 billion.
	5.6 ESMO
Analysis Compares the Rates of Access of Adolescents and Young Adults to Clinical Trials of New Drugs [ESMO] Compared to young adults, adolescents with the same types of cancer have far less access to immunotherapy and/or targeted therapies, according to findings presented at the TAT 2019 – International Congress on Targeted Anticancer Therapies in Paris, France. In addition, young adults could be included in clinical trials of these novel drugs nearly three years earlier than adolescents.
The Lung Immune Prognostic Index Significantly Associates with Outcome Across a Cancer Patient Population [ESMO] Dr. Andrea Varga of the Drug Development Department, Gustave Roussy Cancer Campus in Villejuif, France, explained that the LIPI score has shown an association with patient outcomes following ICI treatment regardless of tumour type.
Rare Cancers a Growing Focus of Early-stage Clinical Trials [ESMO] Sato and his colleagues pooled results from 866 oncology phase 1 trials conducted worldwide for their analysis. These trials, published between 1991 and 2015, involved more than 29,000 patients enrolled to test novel medicines in the first stage of clinical testing.
	6. LUTTE CONTRE LES CANCERS
Cancer services: how much is enough? [Cancer World] In setting the Agenda of sustainable development goals for the near future, the United Nations decided to aim at “reducing premature deaths due to incommunicable diseases by one third by the year 2030”. The exact path to reach that ambitious target is far from clear, but the World Health Organisation (WHO) and the European Society of Medical Oncology (ESMO) are currently joining efforts to blaze a trail for cancer.
	6.10.1 POLITIQUES (USA)
How Pharma Lost Its Edge in Washington [Bloomberg] Major drug company CEOs are about to appear before Congress to address drug pricing—for the first time ever.
	6.4 MÉDICO-ÉCO
Impact investing: a new way to fund cures for cancer [STAT] How do we close the gap between health care companies that need investors and socially minded individuals looking to make their money work for them by also doing good? This is where financial companies can make a huge difference.